Synaptogenix (NASDAQ:TAOX) Stock Price Down 3.2% – Here’s What Happened

Synaptogenix, Inc. (NASDAQ:TAOX)’s stock price traded down 3.2% on Wednesday . The stock traded as low as $3.49 and last traded at $3.61. Approximately 114,507 shares changed hands during trading, a decline of 4% from the average session volume of 118,875 shares. The stock had previously closed at $3.73.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TAOX. Wall Street Zen raised shares of Synaptogenix from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Synaptogenix in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Synaptogenix Stock Down 3.2%

The company has a market capitalization of $26.97 million, a PE ratio of -0.27 and a beta of 1.42. The stock has a 50-day moving average of $4.52 and a 200 day moving average of $4.70.

Synaptogenix (NASDAQ:TAOX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $0.43 earnings per share for the quarter. The business had revenue of $5.96 million during the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.